Twist Bioscience Corporation (NASDAQ:TWST) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Twist Bioscience Corporation (NASDAQ:TWST) have been assigned an average rating of “Moderate Buy” from the ten brokerages that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $84.30.

A number of equities analysts have commented on TWST shares. Evercore cut Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 target price for the company. in a report on Monday, July 6th. Barclays lifted their price target on Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. Leerink Partners set a $80.00 price target on Twist Bioscience in a research report on Friday, May 22nd. Robert W. Baird increased their price objective on Twist Bioscience from $50.00 to $65.00 and gave the company an “outperform” rating in a research note on Tuesday, May 5th. Finally, Canaccord Genuity Group initiated coverage on Twist Bioscience in a report on Monday, June 15th. They issued a “buy” rating and a $90.00 price objective on the stock.

Insiders Place Their Bets

In other news, SVP Paula Green sold 291 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $87.32, for a total value of $25,410.12. Following the transaction, the senior vice president directly owned 120,414 shares of the company’s stock, valued at approximately $10,514,550.48. This trade represents a 0.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jan Johannessen sold 12,000 shares of the business’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $56.12, for a total transaction of $673,440.00. Following the transaction, the director owned 17,754 shares in the company, valued at $996,354.48. The trade was a 40.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 64,983 shares of company stock valued at $5,039,917. Corporate insiders own 3.08% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

A number of large investors have recently made changes to their positions in the stock. Quarry LP acquired a new stake in shares of Twist Bioscience in the third quarter valued at approximately $28,000. Western Wealth Management LLC acquired a new position in Twist Bioscience during the first quarter worth $31,000. Strs Ohio acquired a new position in Twist Bioscience during the first quarter worth $33,000. Strategic Advocates LLC grew its holdings in Twist Bioscience by 562.7% in the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after buying an additional 906 shares in the last quarter. Finally, SBI Securities Co. Ltd. grew its holdings in Twist Bioscience by 68.9% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock valued at $44,000 after buying an additional 571 shares in the last quarter.

Twist Bioscience Price Performance

Shares of TWST stock traded down $3.03 on Friday, reaching $90.64. 1,353,017 shares of the company were exchanged, compared to its average volume of 2,049,859. Twist Bioscience has a 1 year low of $23.30 and a 1 year high of $105.47. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.42 and a current ratio of 2.70. The business has a 50-day moving average price of $74.33 and a 200 day moving average price of $55.97. The company has a market cap of $5.64 billion, a price-to-earnings ratio of -68.15 and a beta of 2.11.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.22). Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The company had revenue of $110.72 million during the quarter, compared to analysts’ expectations of $107.64 million. During the same period in the prior year, the business posted ($0.66) earnings per share. The company’s quarterly revenue was up 19.3% compared to the same quarter last year. Equities research analysts forecast that Twist Bioscience will post -2.02 earnings per share for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.